Hookipa Pharma (NASDAQ:HOOK) Given New $24.00 Price Target at JMP Securities

Hookipa Pharma (NASDAQ:HOOK) had its price target increased by JMP Securities from $23.00 to $24.00 in a report released on Friday morning, Benzinga reports. They currently have a market outperform rating on the stock.

HOOK has been the topic of several other research reports. HC Wainwright boosted their price objective on Hookipa Pharma from $50.00 to $60.00 and gave the stock a buy rating in a report on Wednesday, June 5th. Royal Bank of Canada restated an outperform rating and set a $50.00 price target on shares of Hookipa Pharma in a report on Tuesday, May 21st.

Hookipa Pharma Stock Performance

Shares of NASDAQ:HOOK opened at $4.43 on Friday. The stock has a market capitalization of $43.83 million, a price-to-earnings ratio of -0.92 and a beta of 0.81. Hookipa Pharma has a 1-year low of $4.10 and a 1-year high of $11.30. The company has a 50 day moving average price of $6.38 and a 200 day moving average price of $7.16.

Hookipa Pharma (NASDAQ:HOOK) last released its quarterly earnings data on Thursday, August 8th. The company reported ($1.52) earnings per share for the quarter, missing the consensus estimate of ($1.44) by ($0.08). The company had revenue of $1.29 million for the quarter, compared to the consensus estimate of $5.68 million. Hookipa Pharma had a negative return on equity of 33.33% and a negative net margin of 88.73%. On average, sell-side analysts expect that Hookipa Pharma will post -2.57 EPS for the current fiscal year.

Institutional Investors Weigh In On Hookipa Pharma

A number of institutional investors have recently bought and sold shares of the business. Renaissance Technologies LLC lifted its position in shares of Hookipa Pharma by 38.4% in the second quarter. Renaissance Technologies LLC now owns 302,246 shares of the company’s stock worth $179,000 after purchasing an additional 83,800 shares in the last quarter. Acadian Asset Management LLC increased its stake in Hookipa Pharma by 12.3% in the 2nd quarter. Acadian Asset Management LLC now owns 991,106 shares of the company’s stock valued at $586,000 after buying an additional 108,844 shares during the period. Finally, Virtu Financial LLC purchased a new stake in Hookipa Pharma in the 1st quarter worth approximately $31,000. 63.88% of the stock is currently owned by institutional investors and hedge funds.

About Hookipa Pharma

HOOKIPA Pharma Inc, a clinical-stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors.